Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

Healthy Yuan 2021 Annual Report Interpretation: Net profit attributable to shareholders of the parent company reached 1.328 billion, an increase of 18.57%. Scientific research strength empowers high-quality development.

Published Time:

2022-03-31

On the evening of March 30, 2022, Health Yuan Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Health Yuan", stock code: 600380) disclosed its 2021 annual report. According to the report, the company achieved operating revenue of 15.904 billion yuan, a year-on-year increase of approximately 17.62%; net profit attributable to shareholders of the listed company reached 1.328 billion yuan, a year-on-year increase of approximately 18.57%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 1.225 billion yuan, a year-on-year increase of approximately 26.72%, with double-digit growth in both revenue and profit. In addition, Health Yuan's basic earnings per share were 0.6864 yuan, a year-on-year increase of 19.31%. The board of directors has resolved to distribute a cash dividend of RMB 1.50 per 10 shares (including tax) to all shareholders.

 

 

Business Structure and Product Matrix Optimization: Consolidating the Leading Position in Inhalation Preparations

2021 was the opening year of the "14th Five-Year Plan" and a crucial year for China's new round of medical reforms to enter the "deep water zone." The "three medical" reforms (medical treatment, medical insurance, and medicine) continued to deepen. Facing the continuous deepening of China's medical and health system reform, Health Yuan has always adhered to its vision and mission of "For Health, For Tomorrow" and "Making Good Medicines with Care," focusing on its pharmaceutical main business, firmly implementing the dual-drive strategy of innovative drugs and high-barrier complex preparations, focusing on the three-in-one goal of innovative transformation, integrated operation, and steady growth, and giving full play to the advantages of its integrated production and research and "raw material medicine-preparation integration" full industrial chain. The optimization and adjustment of product structure has entered a new stage.

 

In 2021, Health Yuan's chemical preparation sector achieved significant sales growth, with sales revenue reaching 9.103 billion yuan, a year-on-year increase of 35.88%. Sales in key advantageous areas such as respiratory system, digestive tract, and gonadotropins continued to grow rapidly year-on-year, making a continuously significant contribution to overall revenue. Among them, the inhalation preparation sector's new products accelerated commercialization, achieving outstanding sales results. In 2021, new sales revenue reached 577 million yuan, a year-on-year increase of approximately 658%, further consolidating Health Yuan's position as a "leading domestic inhalation preparation player."

 

At the same time, Health Yuan, through resource integration, product structure adjustment, and increased international certification, has achieved a steady increase in the proportion and profitability of high-end specialty raw materials in the raw material medicine sector; innovative drugs such as the Aprezole series and the high-barrier complex preparation, 亮丙瑞林 microspheres injection, have continued to achieve high growth, providing a powerful engine for the company's rapid development.

 

It is worth noting that in March 2021, the 2020 National Medical Insurance Catalog was officially implemented. Health Yuan's key product, the only domestically produced inhalation preparation, 盐酸左沙丁胺醇雾化吸入溶液, that participated in national negotiations, successfully achieved rapid coverage and sales growth. In June 2021, three inhalation preparation products under Health Yuan, namely 布地奈德混悬液 for inhalation, 异丙托溴铵溶液 for inhalation, and 复方异丙托溴铵溶液 for inhalation, were selected for the fifth batch of national centralized procurement, allowing more Chinese people to use high-quality and low-cost domestic inhalation preparations, breaking the international market monopoly. With the strong support of national negotiations and centralized procurement, Health Yuan's inhalation preparation products have significantly increased their market share, making a key contribution to Health Yuan's revenue growth.

 

 

Full-scale Construction of Innovative High-Barrier Technology Platform; COVID-19 Vaccine V-01 Achieves Research Breakthrough

From 609 million yuan in 2016 to 1.85 billion yuan in 2021, Health Yuan's R&D investment in the past five years has tripled. In 2021, Health Yuan's R&D investment increased by 46.75% year-on-year, accounting for 11.63% of revenue. The company's implemented dual-drive strategy of innovation and high-barrier complex preparations, through continuously increasing R&D investment, actively introducing domestic and foreign senior experts and innovative talents, and overseas strategic alliances, is fully committed to building an innovative high-barrier complex preparation R&D technology platform represented by inhalation administration, antibody technology, and sustained-release microspheres. In 2021, several innovative drug products in Health Yuan's R&D pipeline made significant progress. On the one hand, Health Yuan focuses on pragmatism, starting with the R&D of improved new drugs, striving to promote the launch of new products faster and in greater numbers, and continuously strengthening the sustainable profitability of its product matrix; on the other hand, Health Yuan takes a long-term perspective, firmly and steadily deploying cutting-edge technologies such as AI drug molecular design and synthetic biology, striving to empower the innovation, success rate, and efficiency of the group's R&D pipeline.

 

In 2021, Health Yuan's 丽珠单抗, in cooperation with the Institute of Biophysics, Chinese Academy of Sciences, achieved a milestone breakthrough in the research and commercialization of the recombinant novel coronavirus fusion protein vaccine V-01. Currently, the vaccine commercialization workshop has been completed and put into use, and other listing-related work is underway. As Health Yuan Group's first product to conduct multi-center Phase III clinical trials globally, the smooth progress of its Phase III clinical trials has also accumulated richer resources and experience for the company's subsequent internationalization of innovative drugs in terms of organizational management, partners, team capabilities, and registration applications.

 

In addition, in 2021, Health Yuan Biopharmaceutical Research Institute was officially established, creating six major R&D platforms: industrial strain selection, synthetic biology, biocatalysis, fermentation scaling-up, product extraction, and biochemical raw material medicine. At the same time, Health Yuan reached a strategic cooperation with Tencent Quantum Laboratory to jointly establish a microbial synthetic biology research and related drug development system empowered by quantum AI computing, helping to promote the development and upgrading of China's pharmaceutical and health industry.

 

 

Dedicated to Philanthropy: Contributing to Societal Health

In 2021, Health Yuan formulated the "2021-2025 Energy Conservation and Emission Reduction Work Targets" in line with industry characteristics and national strategic goals, urging various production enterprises to conduct refined management of resource and energy consumption, and putting forward higher requirements for the company's green production and sustainable development work.

 

While focusing on its own efficient development, Health Yuan has always actively assumed social responsibility. In line with the national "14th Five-Year Plan" and the development plan of its operating location, it has devoted itself to social welfare undertakings, striving to achieve a win-win situation in both corporate and social benefits.

 

In 2021, Health Yuan further expanded its responsibility map for the affordable prevention and treatment of chronic diseases. Since the end of 2018, the "Affordable Chronic Disease Prevention and Treatment Public Welfare Project," a collaboration between Health Yuan and Lizhu Group (stock code 000513), has successively entered Sichuan, Shanxi, Gansu, Jilin, Tibet, Henan, Anhui, Hunan, and Jiangxi provinces, covering a total of 15 regions in 8 provinces and 1 autonomous region, providing much-needed medicines to elderly patients with chronic diseases and enhancing the accessibility of medicines for patients.

 

In 2021, the Henan disaster touched the hearts of people across the country. Health Yuan and Lizhu Group quickly joined hands to support the disaster area, donating a total of approximately RMB 10 million in cash and RMB 10 million worth of medicines to assist in related medical relief and post-disaster reconstruction work.

 

 

High Emphasis on Shareholder Returns; Multiple Repurchases Demonstrate Confidence

Following the completion of a total of 700 million yuan in secondary market repurchases in September 2021, Health Yuan launched a new round of secondary market repurchase plan totaling 300-600 million yuan in December 2021, demonstrating the confidence of the board of directors and management in the company's intrinsic value.

 

In addition, based on the 2021 annual operating performance and overall financial status, the board of directors of Health Yuan suggests a steady and robust profit distribution plan for 2021: based on the total share capital of the company on the record date determined by the implementation of the 2021 profit distribution plan, minus the total number of shares in the company's repurchase special securities account, it is proposed to distribute a cash dividend of RMB 1.50 (including tax) per 10 shares to all shareholders of the company.

 

 

Upholding the Dual-Wheel Drive Strategy to Empower Inclusive Healthcare Development

Health Yuan, rooted in patient needs, focusing on rare diseases, and dedicated to meticulous management in the pharmaceutical field, has gradually developed into a comprehensive pharmaceutical enterprise covering multiple fields, including chemical preparations, chemical raw materials and intermediates, traditional Chinese medicine preparations, and diagnostic reagents and equipment. Currently, the group has a total of 179 products under research and development, including 40 high-barrier complex preparations. In 2022, the group will focus on promoting the listing application of tobramycin inhalation solution and strive to be included in the national medical insurance. At the same time, it will actively cooperate and promote the global multi-center Phase III clinical trial of V-01, striving to complete the clinical trial and apply for listing as soon as possible.

 

Looking forward to 2022, Health Yuan stated that the company has always adhered to technological innovation as its foundation, implementing a dual-wheel drive strategy of innovative drugs and high-barrier complex preparation technology platforms, gradually growing into an innovative pharmaceutical enterprise that cares about people's livelihood, is willing to assume social responsibilities, and has industry influence.

 

In this regard, Guosheng Securities believes that Health Yuan's respiratory new products contribute to incremental performance, the R&D pipeline continues to advance, and adjustments are made to the profit forecast. Guosheng Securities gives a buy rating for Health Yuan. Based on the research report data released in the past three years, the research team of Zheng Wei, a researcher at Guolian Securities (Stock Code 601456), has conducted in-depth research on this stock, and the average accuracy of its predictions over the past three years is as high as 96.92%.

 

Source: Financial World